keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy bladder cancer

keyword
https://www.readbyqxmd.com/read/28214574/minimally-invasive-versus-open-approach-for-cystectomy-trends-in-the-utilization-and-demographic-or-clinical-predictors-using-the-national-cancer-database-ncdb
#1
Andrew G Bachman, Alexander A Parker, Marshall D Shaw, Brian W Cross, Kelly L Stratton, Michael S Cookson, Sanjay G Patel
OBJECTIVES: To examine temporal national trends of operative approach for cystectomy and identify demographic or clinical predictive factors that influence choice of approach. METHODS: We performed a retrospective cohort study of patients who underwent cystectomy for bladder cancer between 2010 and 2013 using the National Cancer Database (NCDB). Approach was stratified by open vs. minimally invasive (robotic or laparoscopic). Univariate Pearson chi-square and multivariate logistic regression analysis was used to assess relationships between demographic and hospital factors and the receipt of minimally invasive or open surgical approach...
February 15, 2017: Urology
https://www.readbyqxmd.com/read/28187218/reduced-expression-of-argininosuccinate-synthetase-1-has-a-negative-prognostic-impact-in-patients-with-pancreatic-ductal-adenocarcinoma
#2
Qingqing Liu, John Stewart, Hua Wang, Asif Rashid, Jun Zhao, Matthew H Katz, Jeffrey E Lee, Jason B Fleming, Anirban Maitra, Robert A Wolff, Gauri R Varadhachary, Sunil Krishnan, Huamin Wang
Argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for arginine biosynthesis, is expressed in many types of human malignancies. Recent studies showed that ASS1 may have tumor suppressor function and that ASS1 deficiency is associated with clinical aggressiveness in nasopharyngeal carcinoma, myxofibrosarcomas and bladder cancer. The goal of this study was to evaluate the prognostic impact of ASS1 expression in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included two independent cohorts: untreated cohort, which was comprised of 135 patients with PDAC who underwent pancreatoduodenectomy (PD) without pre-operative neoadjuvant therapy, and treated cohort, which was comprised of 122 patients with PDAC who have completed neoadjuvant therapy and PD...
2017: PloS One
https://www.readbyqxmd.com/read/28182321/detection-and-oncological-effect-of-circulating-tumour-cells-in-patients-with-variant-urothelial-carcinoma-histology-treated-with-radical-cystectomy
#3
Armin Soave, Sabine Riethdorf, Roland Dahlem, Sarah Minner, Lars Weisbach, Oliver Engel, Margit Fisch, Klaus Pantel, Michael Rink
OBJECTIVES: To investigate for the presence of circulating tumour cells (CTC) in patients with variant urothelial carcinoma of the bladder (UCB) histology treated with radical cystectomy (RC), and to determine their impact on oncological outcomes. PATIENTS AND METHODS: We prospectively collected data of 188 patients with UCB treated with RC without neoadjuvant chemotherapy. Pathological specimens were meticulously reviewed for pure and variant UCB histology. Preoperatively collected blood samples (7...
February 9, 2017: BJU International
https://www.readbyqxmd.com/read/28149936/change-in-psoas-muscle-volume-as-a-predictor-of-outcomes-in-patients-treated-with-chemotherapy-and-radical-cystectomy-for-muscle-invasive-bladder-cancer
#4
Homayoun Zargar, Nima Almassi, Evan Kovac, Cesar Ercole, Erick Remer, Brian Rini, Andrew Stephenson, Jorge A Garcia, Petros Grivas
Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker of adverse outcomes among surgical patients. Our aim was to assess for changes in psoas muscle volume (PMV) following administration of neoadjuvant chemotherapy (NAC) in patients with bladder cancer and to examine whether changes in PMV following NAC are predictive of perioperative complications, pathologic response or survival. Methods: During the period of 2009-2013, patients undergoing NAC and radical cystectomy (RC) at our institution with pre and post NAC cross sectional images available were included...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28149933/utility-of-clinical-risk-stratification-in-the-selection-of-muscle-invasive-bladder-cancer-patients-for-neoadjuvant-chemotherapy-a-retrospective-cohort-study
#5
Friedrich-Carl von Rundstedt, Douglas A Mata, Oleksandr N Kryvenko, Anup A Shah, Iny Jhun, Seth P Lerner
Introduction: Level I evidence supports the use of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer prior to radical cystectomy (RC). On average, 30-40% of patients achieve a complete pathologic response (i.e., stage pT0) after receiving NAC. Some centers risk-stratify patients, suggesting that there may be a higher-risk population that would derive the most benefit from NAC. Recently, a risk-stratification model developed at M.D. Anderson Cancer Center (MDACC) specified criteria for clinical staging and patient selection for NAC...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28135678/curative-resection-for-locally-advanced-sigmoid-colon-cancer-using-neoadjuvant-chemotherapy-with-folfox-plus-panitumumab-a-case-report
#6
Kenji Tomizawa, Yuji Miura, Yudai Fukui, Yutaka Hanaoka, Shigeo Toda, Jin Moriyama, Naoko Inoshita, Yukinori Ozaki, Toshimi Takano, Shuichiro Matoba, Hiroya Kuroyanagi
INTRODUCTION: FOLFOX and panitumumab combined chemotherapy plays an important role for metastatic colorectal cancer. However the usefulness of this regimen for neoadjuvant therapy is unclear. CASE REPORT: A 67-year-old man with abdominal pain and pneumaturia was diagnosed with RAS wild-type sigmoid colon cancer with urinary bladder invasion and colovesical fistulas. Because the cancer was considered to be unresectable, a transverse-loop colostomy was performed. Colonoscopy and computed tomography revealed a marked reduction in the size of the primary tumor after six courses of FOLFOX4 (oxaliplatin, leucovorin, and 5-fluorouracil) plus panitumumab...
January 17, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28135623/molecular-biomarkers-to-predict-response-to-neoadjuvant-chemotherapy-for-bladder-cancer
#7
REVIEW
Consuelo Buttigliero, Marcello Tucci, Francesca Vignani, Giorgio V Scagliotti, Massimo Di Maio
Cystectomy is the gold standard for treatment of localized muscle-invasive bladder cancer. However, about 50% of patients develop metastases within 2years after cystectomy and subsequently die for the disease. Neoadjuvant cisplatin-based chemotherapy before cystectomy improves the overall survival in patients with muscle-invasive bladder cancer, and pathological response to neoadjuvant treatment (downstaging to ⩽pT1 at cystectomy) is a strong predictor of better disease-specific survival. Nevertheless, some patients do not benefit from neoadjuvant therapy...
January 11, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28134806/systemic-immunotherapy-for-urothelial-cancer-current-trends-and-future-directions
#8
REVIEW
Shilpa Gupta, David Gill, Austin Poole, Neeraj Agarwal
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28127187/current-concepts-in-the-management-of-muscle-invasive-bladder-cancer
#9
REVIEW
Suprita R Krishna, Badrinath R Konety
Bladder cancer is the ninth most common cancer in the world. Twenty to twenty-five percent of all newly diagnosed bladder cancers are muscle invasive in nature, and further, 20-25% of patients who are diagnosed with high-risk non-muscle invasive disease will eventually progress to muscle invasive disease in due course of time irrespective of adjuvant intravesical therapies. Availability of newer imaging modalities improves appropriate identification of patients with muscle invasive disease. Radical cystectomy remains the mainstay of treatment for management of muscle invasive disease...
March 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28124830/safety-and-feasibility-of-laparoscopic-multivisceral-resection-for-surgical-t4b-colon-cancers-retrospective-analyses
#10
Ryo Takahashi, Suguru Hasegawa, Kenjiro Hirai, Shigeo Hisamori, Koya Hida, Kenji Kawada, Yoshiharu Sakai
INTRODUCTION: Laparoscopic (Lap) surgery has not been established as a standard procedure for locally advanced colon cancers. Here, we evaluated the safety and feasibility of Lap multivisceral resection (MVR) for tumors that had invaded adjacent organs (T4b). METHODS: We performed retrospective analyses using a single institutional database. Eighty-four patients who underwent Lap or open MVR for surgical T4b primary colon cancers satisfied the inclusion criteria...
January 26, 2017: Asian Journal of Endoscopic Surgery
https://www.readbyqxmd.com/read/28105470/bladder-cancer-segmentation-in-ct-for-treatment-response-assessment-application-of-deep-learning-convolution-neural-network-a-pilot-study
#11
COMMENT
Kenny H Cha, Lubomir M Hadjiiski, Ravi K Samala, Heang-Ping Chan, Richard H Cohan, Elaine M Caoili, Chintana Paramagul, Ajjai Alva, Alon Z Weizer
Assessing the response of bladder cancer to neoadjuvant chemotherapy is crucial for reducing morbidity and increasing quality of life of patients. Changes in tumor volume during treatment is generally used to predict treatment outcome. We are developing a method for bladder cancer segmentation in CT using a pilot data set of 62 cases. 65 000 regions of interests were extracted from pre-treatment CT images to train a deep-learning convolution neural network (DL-CNN) for tumor boundary detection using leave-one-case-out cross-validation...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28104421/assessing-cancer-progression-and-stable-disease-after-neoadjuvant-chemotherapy-for-organ-confined-muscle-invasive-bladder-cancer
#12
Meera R Chappidi, Max Kates, Aaron Brant, Alexander S Baras, George J Netto, Phillip M Pierorazio, Noah M Hahn, Trinity J Bivalacqua
OBJECTIVE: To propose and validate a new approach to stratify clinically staged, organ-confined, muscle-invasive bladder cancer patients (cT2N0M0) who are pathologic non-responders to neoadjuvant chemotherapy (NAC) to better characterize NAC non-response. METHODS: We retrospectively identified radical cystectomy patients with cT2N0M0 disease at our institution (2005-2014) and in the National Cancer Database (2004-2012) for external validation. Patients were stratified as stable (pT2N0M0) or progressors (>pT2 or pN+)...
January 16, 2017: Urology
https://www.readbyqxmd.com/read/28078533/risk-factors-for-intravesical-recurrence-after-nephroureterectomy-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#13
Ryo Yamashita, Reiko Watanabe, Ichiro Ito, Hideo Shinsaka, Masafumi Nakamura, Masato Matsuzaki, Masashi Niwakawa
PURPOSE: To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). METHODS: We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients)...
January 11, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28049550/gec-estro-acrop-recommendations-for-performing-bladder-sparing-treatment-with-brachytherapy-for-muscle-invasive-bladder-carcinoma
#14
Bradley R Pieters, Elzbieta van der Steen-Banasik, Geert A Smits, Marisol De Brabandere, Alberto Bossi, Erik Van Limbergen
The standard treatment for muscle-invasive bladder cancer (MIBC) is a radical cystectomy with pelvic lymph node dissection with or without neoadjuvant chemotherapy. In selected cases a bladder sparing approach is possible, for example a limited surgical excision combined with external beam radiotherapy and brachytherapy. To perform brachytherapy flexible catheters have to be implanted in the bladder wall. The implantation is done either by the open retropubic approach or the endoscopic surgical approach. The largest experience for brachytherapy is with low-dose rate and pulsed-dose rate, although some short-term experience with high-dose rate is also reported...
December 31, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28041996/utilization-of-perioperative-systemic-chemotherapy-in-upper-tract-urothelial-carcinoma
#15
Greg E Gin, Nora H Ruel, Steven V Kardos, John P Sfakianos, Edward Uchio, Clayton S Lau, Bertram E Yuh
INTRODUCTION: Evidence for the use of perioperative chemotherapy (PC) in upper tract urothelial carcinoma (UTUC) is largely derived from level I evidence for invasive urothelial carcinoma of the bladder (UCB). There has been an increase in PC for urothelial carcinoma of the bladder, as it has disseminated into clinical practice. Therefore, we sought to not only analyze trends in the utilization of PC in UTUC, but also assess factors associated with its use in a large cancer registry database...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28035325/effect-of-neoadjuvant-chemotherapy-on-renal-function-following-radical-cystectomy-is-there-a%C3%A2-meaningful-impact
#16
Thenappan Chandrasekar, Neil Pugashetti, Blythe Durbin-Johnson, Marc A Dall'Era, Christopher P Evans, Ralph W deVere White, Stanley A Yap
Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6-12 months follow-up), and then classified by CKD staging...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035322/micropapillary-bladder-cancer-insights-from-the-national-cancer-database
#17
Wilson Sui, Justin T Matulay, Maxwell B James, Ifeanyi C Onyeji, Marissa C Theofanides, Arindam RoyChoudhury, G Joel DeCastro, Sven Wenske
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports. We sought to use a population-level cancer database to assess survival outcomes in patients treated with surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases of MPBC and UC using International Classification of Disease-O-3 morphologic codes between 2004-2014...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28025135/doxorubicin-enhances-the-capacity-of-b-cells-to-activate-t-cells-in-urothelial-urinary-bladder-cancer
#18
A Ali Zirakzadeh, Johan Kinn, David Krantz, Robert Rosenblatt, Malin E Winerdal, Jin Hu, Ciputra Adijaya Hartana, Christian Lundgren, Emma Ahlén Bergman, Markus Johansson, Benny Holmström, Johan Hansson, Alexander Sidikii, Janos Vasko, Per Marits, Amir Sherif, Ola Winqvist
Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4(+) T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody...
December 24, 2016: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/27991416/small-cell-carcinoma-of-the-bladder-20-year-single-institution-retrospective-review
#19
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, Eric M Horwitz, Robert G Uzzo, Richard E Greenberg, Rosalia Viterbo, Daniel M Geynisman, Alexander Kutikov, Elizabeth R Plimack, Marc C Smaldone, Yu-Ning Wong, Marijo Bilusic
INTRODUCTION: Small-cell carcinoma of the bladder is a poorly differentiated neoplasm with aggressive behavior. We analyzed clinical outcomes of patients who were treated at our institution to identify an optimal treatment strategy. MATERIALS AND METHODS: Retrospective chart analysis was performed for patients who were treated for small-cell carcinoma of the bladder at Fox Chase Cancer Center between 1995 and 2015. Survival was compared between different treatment periods (before January 2010 vs...
September 30, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27980085/the-feasibility-and-effectiveness-of-robot-assisted-radical-cystectomy-after-neoadjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer
#20
Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Tohru Yoneyama, Yuki Tobisawa, Atsushi Yamauchi, Toru Shimazui, Mikinobu Ohtani
OBJECTIVES: The aim of this study was to compare 29 muscle-invasive bladder cancer patients who received neoadjuvant chemotherapy (NAC) followed by immediate robot-assisted radical cystectomy (RARC) with those who underwent minimum-incision endoscopic RC (MIE-RC). METHODS: We retrospectively reviewed the charts of 430 consecutive patients who underwent RC and bilateral pelvic node dissection (PLND) between May 1994 and July 2016. Our study focused on patients with MIBC who had histologically confirmed stage T2-T4aN0M0 urothelial carcinoma of the bladder and received NAC prior to surgery...
December 15, 2016: Japanese Journal of Clinical Oncology
keyword
keyword
40909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"